Aducanumab and Alzheimer Disease Clinical Trials

Episode 24,  Dec 18, 2020, 02:00 PM

Welcome to the NeurologyLive Mind Moments podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.

In this episode, we're joined by Lon Schneider, MD, MS, Della Martin Chair in Psychiatry and Neuroscience, University of Southern California Keck School of Medicine; Marwan Sabbagh, MD, director, Lou Ruvo Center for Brain Health, Cleveland Clinic; Stephen Salloway, MD, MS, director, Neurology and the Memory and Aging Program, Butler Hospital; Richard S. Isaacson, MD, director, Alzheimer’s Prevention Clinic, Weill Cornell Medicine; and Anton Porsteinsson, MD, director, Alzheimer's Disease Care, Research, and Education Program, University of Rochester.

Each of these experts provided their perspective and insight into what’s been happening in the conversations around aducanumab and why there is some controversy around its clinical trial data, as well as how all of this speaks to the intricacies and difficulties in actually conducting clinical trials in Alzheimer disease.

Part 1 – Support, Skepticism, and Statistics: The Aducanumab Saga

Thanks for listening to the NeurologyLive Mind Moments podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit